

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/535,307
				Confirmation Number	3693
				Filing Date	May 18, 2005
				First Named Inventor	Andrew N. MARGIORIS
				Art Unit	Not Yet Known
				Examiner Name	Not Yet Known
Sheet	1	of	2	Attorney Docket Number	Q87992

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
/CB/		Corticotropin-Releasing Hormone augments Proinflammatory Cytokine Production from Macrophages In Vitro and in Lipopolysaccharide-Induced Endotoxin shock in Mice; Agelaki, et al.; Infection and Immunity, November 2002, p. 6068-6074; Vol. 70, No. 11	
/CB/		Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin; Agnello, et al.; The American Physiological Society; E757-E760; XP-002247896	
/CB/		Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin; Agnello, et al.; AJP Endocrinology and Metabolism; http://ajpendo.physiology.org/cgi/content/full/275/5/E757	
/CB/		Receptor-mediated immunomodulation by corticotrophin-releasing factor; Audhya T, et al., Entrez PubMed; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi	
/CB/		mRNA expression profiles for corticotrophin-releasing factor 9CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues; Baigent, et al.; Journal of Molecular Endocrinology (2000) 25, 43-52	
/CB/		Annals of the New York Academy of Sciences, Volume 917 2000; pp 290-296; The Peripheral CRH/Urocortin system; Bamberger, et al.; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
/CB/		CRH-like peptides protect cardiac myocytes from lethal ischaemic injury; Brar BK, et al.; Pub Med; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
/CB/		Local Secretion of Corticotropin-releasing Hormone in the Joints of Lewis Rats with Inflammatory Arthritis; Crofford, et al.; The Journal of Clinical Investigation, Inc., Volume 90, December 1992, 2555-2564	
/CB/		Corticotropin-Releasing hormone in Synovial Fluids and Tissues of patients with Rheumatoid Arthritis and osteoarthritis; Crofford, et al.; The Journal of immunology, Vol. 151, 1587-1596, No. 3, august 1, 1993	
/CB/		The CRF peptide family and their receptors: yet more partners discovered; Dautzenberg, et al.; Trends in Pharmacological Sciences; Vol. 23, No. 2, February 2002	
/CB/		Corticotropin-releasing Hormone Induces Fas Ligand Production and Apoptosis in PC12 Cells via Activation of p38 Mitogen-activated Protein Kinase; Dermitzaki, et al.; The Journal of Biological Chemistry, vol. 277, No. 14; April 5, 2002; pp. 12280-12287	
/CB/		Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory Cytokines and Susceptibility to Disease; Elenkov, et al. TEM, vol. 10, No. 9, 1999; pp. 359-379	
/CB/		Annals of the New York Academy of Sciences; Stress, Corticotropin-Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects; Elenkov, et al.; Vol. 876; pp. 1-13; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
/CB/		Urocortin 1 and urocortin 2 induce macrophage apoptosis via CRFR ₂ ; Tsatsanis, et al.; 2005 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies;	
Examiner Signature		/Christina Borgeest/ (01/08/2008)	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO		INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		<i>Complete if Known</i>	
				Application Number	10/535,307
		Confirmation Number	3693		
		Filing Date	May 18, 2005		
		First Named Inventor	Andrew N. MARGIORIS		
		Art Unit	Not Yet Known		
		Examiner Name	Not Yet Known		
		Attorney Docket Number	Q87992		
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
/CB/		Anal. of the New York Academy of Sciences; Stress, Corticotropin-Releasing Hormone, Glucocorticoids, and the Immune/Inflammatory Response: Acute and Chronic Effects; Elenkov, et al.; Volume 8760.1999.1-13	
/CB/		Autocrine or paracrine inflammatory actions of corticotrophin-releasing hormone in vivo.; Karalis, et al.; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
/CB/		Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis; Kawahito, et al.; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Gut ; 1995 Oct; 37(4):544-51	
/CB/		Urocortin Expression in Synovium of Patients with Rheumatoid Arthritis and osteoarthritis: Relation to Inflammatory Activity; Kohno, et al.; The Journal of Clinical Endocrinology & Metabolism 86(9) 4344-4352	
/CB/		Differential Actions of peripheral Corticotropin-Releasing Factor (CRF), Urocortin II, and Urocortin III on Gastric Emptying and Colonic Transit in Mice: role of CRF Receptor Subtypes 1 and 2; Martinez, et al.; The Journal of Pharmacology and Experimental Therapeutics; Vol. 301, No. 2; pp. 611-617	
/CB/		Human urocortin II, a new CRF-related peptide, displays selective CRF 2-mediated action on gastric transit in rats; Million, et al.; American Journal of Physiology -- Gastrointestinal and Liver Physiology; September 21, 2001; pp. G34-G40.	
/CB/		Urocortin and corticotrophin-releasing factor receptor expression in the human colonic mucosa; Muramatsu, et al.; Peptides 21 92000) 1799-1809	
/CB/		Urocortin, a member of the corticotrophin-releasing factor family, in normal and diseased heart; Nishikimi, et al.; American Journal of Physiology Heart Circ Physiol 279: H:3031-H3039, 2000	
/CB/		Urocortin, But Not Urocortin II, Protects Cultured Hippocampal Neurons From oxidative and Excitotoxic Cell Death via Corticotropin-Releasing Hormone Receptor Type I; Pedersen, et al.; The Journal of Neuroscience, January 15, 2002, 22(2):404-412	
/CB/		Corticotropin Releasing Factor Receptors and Their Ligand Family; Perrin, et al.; Academy of Science, Volume 8850.1999.312-328; http://lib3.tufts.edu:2301/gw1/ovidweb.cgi	
/CB/		Stress and Autoimmunity; The Neuropeptides Corticotropin-Releasing Factor and Urocortin Suppress Encephalomyelitis via Effects on Both the Hypothalamic-Pituitary-Adrenal Axis and the Immune System; Poliak, et al.; the American Association of immunologists; 1997; 158: 5751-5756	
/CB/		Corticotropin-Releasing hormone induces Skin Mast Cell Degranulation and Increased Vascular Permeability, A Possible Explanation for Its Proinflammatory Effects; The Endocrine Society; Vol. 139. No. 1;	
/CB/		Urocortin, a corticotrophin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats; Turnbull, et al.; Pub Med; National Library of Medicine; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
/CB/		Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotrophin-releasing factors; Vaughan, et al.; Letters to Nature; Vol. 378, November 16, 1995	
/CB/		Corticotropin-releasing factor receptors in mouse spleen: identification of receptor-bearing cells as resident macrophages; Webster, et al.; Pub Med; National Library of Medicine; July 1990; 127(1):440-52; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?	
/CB/		Corticotropin-Releasing Hormone and Inflammation; Annals of the New York Academy of Sciences; Volume 840; 1998; pp 21-32	
/CB/		Urocortin in Human Gastric Mucosa: Relationship to Inflammatory Activity; Chatzaki, et al.; The Journal of Clinical Endocrinology & Metabolism; 88(1):478-483	
Examiner Signature		/Christina Borgeest/ (01/08/2008)	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number 10535307

Filing Date 2005-12-07

First Named Inventor Andrew N. MARGIORIS, et al.

Art Unit 1815

Examiner Name Not Yet Assigned

Attorney Docket Number Q87992

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/CB/	1	6765008	B1	2004-07-20	CHEN, Y.L.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10535307
Filing Date	2005-12-07
First Named Inventor	Andrew N. MARGIORIS, et al.
Art Unit	1615
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q87992

1		<input type="checkbox"/>
---	--	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Christina Borgeest/ (01/08/2008)	Date Considered	
--------------------	-----------------------------------	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.